Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (115513)	10/23/2000 4:45:07 PM
From: Jenna	Respond to of 120523

Biotech stocks move up By Ted Griffith, CBS.MarketWatch.com Last Update: 12:19 PM ET Oct 23, 2000 NewsWatch Latest headlines NEW YORK (CBS.MW) -- Led by the stock of Vertex Pharmaceuticals, biotechnology shares surged higher for the second straight trading session Monday. The Amex Biotechnology Index ($BTK: news, msgs) rose 5.6 percent and the Nasdaq Biotechnology Index ($IXBT: news, msgs) added 3.9 percent. Vertex Pharmaceuticals (VRTX: news, msgs) shares surged after the Cambridge, Mass.-based biotech said Monday its partner, British pharmaceutical giant GlaxoWellcome (GLX: news, msgs), has received approval from the European Commission to market the HIV drug Agenerase in all 15 countries of the European Union. Agenerase was developed by Vertex. Vertex also said Monday that it has added four new drug candidates to its pipeline of potential products. The drugs have the potential to treat viral infections, autoimmune diseases, cardiovascular disorders and inflammation, according to Vertex. Shares of Vertex jumped $13.19, or 16.5 percent, to $92.94. GlaxoWellcome's American-listed shares rose $1.56 to $58.06. Carolyn Pratt, an analyst with Needham & Co., said she was encouraged by Vertex's announcement about the additional product candidates. "To me, it's great news because it shows Vertex is generating new product candidates to fill its pipeline," Pratt said. "It also shows that Vertex's drug-discovery approach is working." As for the European approval of Agenerase, Pratt said she was not surprised by the clearance. "It was expected," she said. "It was something the company had been hoping for." Elsewhere, Aurora Biosciences' stock built on Friday's gains, climbing $3.39 to $55.38 Monday. Aurora Biosciences (ABSC: news, msgs) said Friday it has acquired Quorum Sciences Inc. for 81,300 shares of Aurora stock, worth $3.8 million based on Aurora's closing price of $47 Thursday. Privately held Quorum develops antibacterial agents. San Diego-based Aurora develops and sells drug-discovery technologies.

To: Jenna who wrote (115513)	10/24/2000 8:34:49 AM
From: johnsto1	Respond to of 120523

askresearch.com Todays WSJ...BOUT October 23, 2000 -------------------------------------------------------------------------------- About Inc. Posts Strong Revenue, Says Profit Will Come in 1st Period A WSJ.COM News Roundup NEW YORK -- About Inc. reported a third-quarter loss, but results at the fast-growing Web guide beat Wall Street expectations and the company said it remains on track to post an operating profit in the first quarter. The company posted a net loss of $14.6 million, or 80 cents a share, compared with a loss of $13.2 million, or $1.08 a share, in the year-earlier period. (The company had about 18.3 million shares outstanding in the third quarter, up from 12.2 a year earlier.) Excluding noncash compensation and goodwill-amortization charges, About had a loss of $3.2 million, or 18 cents a share, compared with a loss of $12.7 million, or $1.04 a share, in the year-earlier period, on a similar basis. Analysts surveyed by First Call/Thomson Financial were expecting a loss, excluding items, of 21 cents a share. Revenue more than tripled to $26.8 million from $7.9 million in the year-ago quarter, and was up 33% sequentially from $20.1 million in the second quarter. Average daily page views rose 48% to 34.1 million in September, from 23 million in June. Cash, cash equivalents and investments totaled $133.8 million at Sept. 30. *10 mil float Short Interest As of 8-Sep-2000 Shares Short 3.76M Percent of Float 34.8% Shares Short (Prior Month) 3.47M Short Ratio 9.01 Daily Volume 417.0K biz.yahoo.com